Cefdinir for Oral Suspension USP, 250 mg/5mL, packaged in 60 mL bottles, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland, Manufactured by: Lupin Limited, Mandideep, India, NDC 68180-723-20
Published July 29, 2020 · Recall initiated: July 2, 2020
Summary
FDA records drug Class II recall D-1406-2020, published July 29, 2020 and initiated July 2, 2020. Recalling firm: Lupin Pharmaceuticals Inc.; Status: Terminated; Reported quantity: 35,928 bottles; Lot: Lot # F802189, Exp 10/2020, F900240, Exp 1/2021. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Superpotent Drug: Out-of-specification (OOS) result observed in an assay test of retention samples.
What to do
Voluntary: Firm initiated · Letter
Get an email if CEFDINIR has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- CEFDINIR
- Manufacturer
- Lupin Pharmaceuticals Inc.
- Distributor
- U.S.A. Nationwide
- UPC
- 0368180723042
- Lot
- Lot # F802189, Exp 10/2020, F900240, Exp 1/2021
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDACefdinir for Oral Suspension USP, 250 mg/5 mL, packaged in a 60 mL bottle, Rx only, Manufactured for: LupinJune 5, 2024
- FDACefdinir for Oral Suspension USP 125 mg/5 mL (60 mL when reconstituted), 60 mL bottle, Rx only, ManufacturedMay 22, 2024
- FDACefdinir for Oral Suspension USP 250 mg/5 mL (60 mL when reconstituted), 60 mL bottle, Rx only, ManufacturedMay 22, 2024
- FDAFamotidine Injection, USP, 20 mg/2mL, 2 mL vial, Rx only, Single Dose Vial, For Intravenous Use Only AfterJuly 29, 2020
- FDAMystic Shield PROTECTION, ALCOHOL ANTISEPTIC 70%, Topical Solution, Antiseptic Hand Rub, Non-sterile Solution,July 29, 2020
- FDACefdinir for Oral Suspension USP, 250 mg/5mL,100 mL bottle, Rx only, Manufactured for: Lupin Pharmaceuticals,November 13, 2019
Questions about this recall
Was Cefdinir for Oral Suspension USP, 250 mg/5mL, packaged in 60 mL bottles, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland, Manufactured by: Lupin Limited, Mandideep, India, NDC 68180-723-20 recalled?
Yes. FDA published recall D-1406-2020 on July 29, 2020. Reported hazard: Superpotent Drug: Out-of-specification (OOS) result observed in an assay test of retention samples.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: CEFDINIR. UPC: 0368180723042.